Abstract
Type 2 diabetes mellitus (DM2) has increased 41% in the United States, with an estimated one third undiagnosed and another 41 million with prediabetes. Hypertension affects 20% to 60% of all diabetics, contributing to up to 75% of deaths due to cardiovascular disease. These staggering statistics make it imperative that hypertensive patients who are at risk for DM2 are identified and treated early. Numerous studies have been done involving choice of antihypertensive in established diabetics, and a slowing or halting of the progression in the development of diabetes in these patients has been noticed. However, to date, nothing is conclusive. For now, following the JNC 7 guidelines of using a diuretic as monotherapy or in combination with an angiotensin-converting enzyme inhibitor (ACEI), angiotensin II-receptor blocker (ARB), β-blocker, or calcium channel blocker may be prudent. Two current studies, the DREAM trial and the ONTARGET trial, may shed more light as to whether ACEIs or ARBs have a preferred niche in initial treatment of the hypertensive patient who is at risk for diabetes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Holcomb SS: Diabetes update: 2005 ACE guidelines. Nurse Pract 2005, 30:12–14.
Holcomb SS: Treating hypertension in diabetes patients. Nurse Pract 2004, 29:13–15.
National Heart, Lung, and Blood Institute (NHLBI): Complete report: the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2004. http://www.nhlbi.nih.gov/guidelines/ hypertension/jncfull.pdf. Accessed June 25, 2005. This is the consensus report published through the National Institutes of Health to direct providers in the guidelines for preventing, detecting, evaluating, and treating high blood pressure in patients. The guideline is based on the most recent evidence-based medicine.
Magill MK, Gunning K, Saffel-Shrier S, Gay C: New developments in the management of hypertension. Am Fam Phys 2003, 68:853–857.
Townsend MS, Fulgoni VL 3rd, Stern JS, et al.: Low mineral intake is associated with high systolic blood pressure in the Third and Fourth National Health and Nutrition Examination Surveys: Could we all be right? Am J Hypertension 2005, 18:261–269.
Lopez-Ridaura F, Willett WC, Rimm EB, et al.: Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004, 27:134–139. In this paper, the roles, at the cellular level, that key minerals may play in the development of diabetes and hypertension (specifically magnesium) are discussed.
The DREAM Trial Investigators: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519–1527.
Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation fat cells. Hypertension 2002, 40:609–611. As we try to understand how to prevent disease as well as how to appropriately treat medical conditions, what goes on at the cellular level is extremely important. This paper addresses an importance of understanding how excess calories are not stored in adipose tissue but rather in organs, muscles, and other tissues, which become insulin resistant, and that the use of angiotensin blockade may help redistribute storage and increase insulin sensitivity.
Niklason A, Hedner T, Niskanen L, et al.: Development of diabetes is retarded by ACE inhibition in hypertensive patients: a subanaylsis of the Captopril Prevention Project (CAPP). J Hypertens 2004, 22:645–652.
Khan BV, Sola S, Lauten WB, et al.: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004, 27:1712–1715.
Ong HT, Cheah JS: Choice of antihypertensive drug in the diabetic patient. Medscape General Medicine 2005, http:// www.medscape.com/viewprogram/3989_pnt.
Abbott KC, Bakris GL: What have we learned from the current trials? Med Clin North Am 2004, 88:189–207.
Vidt DG: The ALLHAT trial: diuretics are still the preferred initial drugs for high blood pressure. Cleveland Clin J Med 2003, 70:263–269.
National Heart, Lung, and Blood Institute: ALLHAT information for health professionals: quick reference for health care providers.
Lopez-Sendon J, Swedberg k, McMurray J, et al.: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. http://www.guidelines.gov/summary/ sumary.aspx?doc_id=5747&nbr=38. Accessed June 22, 2005.
Berra K, Hughes S: Pharmacologic agents to reduce cardiovascular disease risk for the patient with insulin resistance. In Reducing Cardiovascular Risk in the Insulin Resistant Patient. Edited by Lamendola C, Mason CM. New York: Preventive Cardiovascular Nurses Association; 2004:45–65. http://www.nhlbi.nih.gov/ health/allhat/qckref.htm|url. Accessed June 24, 2005.
Weiss SV, Mottur-Pilson C: The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. http://www.guidelines.gov/summary/summary. aspx?doc_id=3739&nbr=29. Accessed June 22, 2005.
Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med 2002, 346:393–403.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holcomb, S.S. Selection of antihypertensive agents in patients at risk for diabetes. Current Science Inc 7, 461–465 (2005). https://doi.org/10.1007/s11906-005-0042-z
Issue Date:
DOI: https://doi.org/10.1007/s11906-005-0042-z